Neurogene Inc. (NGNE)
- Previous Close
30.64 - Open
31.02 - Bid 31.32 x 100
- Ask 31.87 x 100
- Day's Range
29.57 - 31.60 - 52 Week Range
12.20 - 53.00 - Volume
82,627 - Avg. Volume
139,437 - Market Cap (intraday)
409.528M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
46.67
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
www.neurogene.comRecent News: NGNE
Performance Overview: NGNE
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NGNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NGNE
Valuation Measures
Market Cap
409.53M
Enterprise Value
275.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.94%
Return on Equity (ttm)
-25.52%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
13.65M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
197.16M
Total Debt/Equity (mrq)
8.05%
Levered Free Cash Flow (ttm)
-16.42M
Research Analysis: NGNE
Company Insights: NGNE
NGNE does not have Company Insights